MediWound Ltd.
MDWD Nasdaq· Medicinal Chemicals & Botanical Products
Last close · Oct 26, 2026
$12.07
KIRA · Stoqly’s AI analyst, in plain words
- MediWound Ltd. had $17.0M of revenue in fiscal 2025, down 16.1% on the year before. Over five years, revenue changed −4.9% a year on average.
- Its operating margin was −149.0%, down 53.0 pts: of every 100 in sales, about −149 is left after running the business.
- MediWound Ltd. lost $23.9M in fiscal 2025.
- Free cash flow was −$21.6M in fiscal 2025, −127.5% of revenue.
Market cap
$137M
P/E
—
Revenue
$17.0M
Net income
−$23.9M
Free cash flow
−$21.6M
Operating margin
−149.0%
MediWound Ltd. in 30 seconds · fiscal 2025
Are sales growing?
−16.1%
No. Sales fell 16.1% last year.
Does it make a profit?
−140.8%
No. It lost money last year.
Does profit turn into cash?
−127.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What MediWound Ltd. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 5, 2026
- Legal name
- MediWound Ltd.
- CIK
- 0001593984
MediWound Ltd. · MDWD
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $23.8M | $26.5M | $18.7M | $20.2M | $17.0M |
| Revenue growth | 9.2% | 11.5% | −29.5% | 8.2% | −16.1% |
| Gross margin | 36.9% | 49.7% | 19.1% | 13.0% | 19.2% |
| Operating margin | −47.2% | −31.5% | −81.8% | −95.9% | −149.0% |
| Net income | −$13.6M | −$19.6M | −$6.7M | −$30.2M | −$23.9M |
| Net margin | −57.0% | −74.0% | −35.9% | −149.5% | −140.8% |
| Diluted EPS | −$3.48 | −$3.93 | −$0.75 | −$3.03 | −$2.10 |
| Cash | |||||
| Cash from operations | −$8.9M | −$11.9M | −$10.5M | −$13.6M | −$16.1M |
| Capital expenditure | $0.5M | $0.6M | $6.5M | $6.3M | $5.5M |
| Free cash flow | −$9.4M | −$12.4M | −$16.9M | −$19.9M | −$21.6M |
| FCF margin | −39.6% | −47.0% | −90.6% | −98.4% | −127.5% |
| Share count change | −85.7% | 28.1% | 80.7% | 10.5% | 14.2% |
| Debt and strength | |||||
| Cash and short-term investments | $11.0M | $33.9M | $11.9M | $9.2M | $4.8M |
| Shareholders' equity | −$4.6M | $10.9M | $31.6M | $31.2M | $43.6M |
| Current ratio | 1.4x | 3.8x | 2.7x | 2.0x | 2.3x |
| Interest coverage | −4.8x | −0.7x | −8.1x | −1.5x | −10.3x |
| Returns and quality | |||||
| Return on equity | −1,007.5% | −619.0% | −31.6% | −96.3% | −63.9% |
| Return on tangible equity | — | −183.5% | −21.4% | −97.3% | −54.8% |
| Piotroski F-score | 4 | 4 | 1 | 1 | 4 |
| Altman Z'' | −27.1 | −7.4 | −6.1 | −7.8 | −6.9 |
Insiders bought, 12 months
$0.1M
3 insiders
Insiders sold, 12 months
$0.1M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
MediWound Ltd. · MDWD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $12.07 a share, the company is worth $137M.
Source: SEC EDGAR XBRL filings (CIK 0001593984). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.